Crisaborole Ointment Effect on Global Atopic Dermatitis Severity and Early Relief in Pruritus: Pooled Results From Two Phase 3 Clinical Trials

被引：0

作者：

Paller, Amy S. ^{[1
]}

Yosipovitch, Gil ^{[2
]}

Tom, Wynnis L. ^{[3
,4
]}

Lebwohl, Mark ^{[5
]}

Boguniewicz, Mark ^{[6
,7
]}

Call, Robert S. ^{[8
]}

Eichenfield, Lawrence F. ^{[3
,4
]}

Forsha, Douglass W. ^{[9
]}

Rees, William C. ^{[10
]}

Simpson, Eric L. ^{[11
]}

Gold, Linda F. Stein ^{[12
]}

Zaenglein, Andrea L. ^{[13
]}

Tallman, Anna M. ^{[14
]}

Tan, Bill ^{[14
]}

Hebert, Adelaide A. ^{[15
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[3] Rady Childrens Hosp San Diego, San Diego, CA USA

[4] Univ Calif San Diego, San Diego, CA 92103 USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] Natl Jewish Hlth, Denver, CO USA

[7] Univ Colorado, Sch Med, Denver, CO USA

[8] Clin Res Partners, Richmond, VA USA

[9] Jordan Valley Dermatol & Res Ctr, W Jordan, UT USA

[10] PI Coor Clin Res, Burke, VA USA

[11] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[12] Henry Ford Hlth Syst, Detroit, MI USA

[13] Penn State Univ, Hershey, PA USA

[14] Pfizer Inc, New York, NY USA

[15] Univ Texas Houston, Med Ctr, Houston, TX USA

来源：

PEDIATRICS | 2018年 / 142卷

关键词：

D O I：

10.1542/peds.142.1_MeetingAbstract.815

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

815

引用

页数：2

共 50 条

[21] Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis [J].

Paller, A. S. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) :663-664

[22] Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis [J].

Paller, Amy ;

Tom, Wynnis ;

Lebwohl, Mark M. ;

Blumenthal, Robin L. ;

Boguniewicz, Mark ;

Eichenfield, Lawrence S. ;

Forsha, Douglass W. ;

Simpson, Eric L. ;

Gold, Linda Stein ;

Zaenglein, Andrea L. ;

Call, R. S. ;

Rees, W. C. ;

Zane, L. T. ;

Hebert, A. A. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) :AB86-AB86

[23] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials [J].

Igarashi, Atsuyuki ;

Tsuji, Gaku ;

Fukasawa, Shuichi ;

Murata, Ryusei ;

Yamane, Satoshi .

JOURNAL OF DERMATOLOGY, 2024, 51 (11) :1404-1413

[24] Crisaborole Topical Ointment, 2%, a novel nonsteroidal, anti-inflammatory, topical, phosphodiesterase 4 inhibitor, reduced pruritus and signs of atopic dermatitis in 2 phase 3 studies in children and adults with mild-to-moderate atopic dermatitis [J].

Zane, Lee Thomas ;

Hebert, Adelaide A. ;

Eichenfield, Lawrence F. ;

Lebwohl, Mark G. ;

Paller, Amy S. ;

Simpson, Eric L. ;

Tom, Wynnis L. ;

Hughes, Matty H. .

JOURNAL OF IMMUNOLOGY, 2016, 196

[25] Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies [J].

Simpson, Eric L. ;

Augustin, Matthias ;

Thaci, Diamant ;

Misery, Laurent ;

Silverberg, Jonathan I. ;

Armstrong, April W. ;

Fuxench, Zelma C. Chiesa ;

Kuligowski, Michael E. ;

Venturanza, May E. ;

Sun, Kang ;

Papp, Kim .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) :AB178-AB178

[26] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials [J].

Eichenfield, Lawrence F. ;

Boguniewicz, Mark ;

Simpson, Eric L. ;

Blauvelt, Andrew ;

Gooderham, Melinda ;

Lain, Edward ;

Chu, David H. ;

Higham, Robert C. .

BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 :II10-II11

[27] ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS [J].

Eichenfield, L. ;

Boguniewicz, M. ;

Simpson, E. ;

Blauvelt, A. ;

Gooderham, M. ;

Lain, E. ;

Chu, D. ;

Higham, R. .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) :S91-S91

[28] Long-term safety and disease control with Ruxolitinib cream in atopic dermatitis: Pooled results from two phase 3 studies [J].

Papp, K. ;

Szepietowski, J. C. ;

Kircik, L. ;

Toth, D. ;

Eichenfield, L. F. ;

Forman, S. B. ;

Kuligowski, M. E. ;

Venturanza, M. E. ;

Ren, H. ;

Simpson, E. L. .

EXPERIMENTAL DERMATOLOGY, 2021, 30 :43-43

[29] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials [J].

Eric L. Simpson .

Dermatology and Therapy, 2017, 7 :243-248

[30] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials [J].

Simpson, Eric L. .

DERMATOLOGY AND THERAPY, 2017, 7 (02) :243-248

← 1 2 3 4 5 →